Abstract

Recently, red blood cell transfusions have been advocated for patients with acute myocardial infarction when hemoglobin falls below 10 g/dL, based on the Myocardial Ischemia and Transfusion (MINT) trial, which showed a trend to benefit, compared to deferring transfusion until hemoglobin was below 7-8 g/dL. However, the trial failed to reach its primary endpoint. A meta-analysis including the totality of published relevant evidence does not support the superiority of one blood transfusion strategy over another. Advocating a policy of more liberal transfusion for patients with myocardial infarction and anemia is premature, potentially erroneous, and harmful.

Downloads

Authors

Aryeh Shander - TeamHealth Department of Anesthesiology and Critical Care, Englewood Health, New Jersey, United States of America

Kevin M. Trentino - Medical School, The University of Western Australia, Perth, Australia https://orcid.org/0000-0002-8768-9263

Caroline Evans - Department of Anaesthesia and Intensive Care, University Hospital of Wales, Cardiff, United Kingdom

John Cleland - British Heart Foundation Centre of Research Excellence. School of Cardiovascular and Metabolic Health, University of Glasgow, United Kingdom https://orcid.org/0000-0002-1471-7016

  • Abstract viewed - 171 times
  • pdf downloaded - 99 times